Stock Track | Jenscare Scientific Soars 6.43% Intraday on First Revenue from Product Commercialization
Stock Track
Mar 27
Jenscare Scientific's stock surged 6.43% during intraday trading on Friday, showing significant investor interest despite the company's financial results.
The medical device company reported widening its attributable loss for 2025 to 271.2 million yuan from 177.5 million yuan a year prior. However, the market responded positively as Jenscare recorded its first revenue of 90.6 million yuan, compared to no revenue in the previous year.
According to the company's filing, this revenue was attributed to higher sales volume resulting from the commercialization of its interventional products for the treatment of structural heart diseases, marking an important milestone in the company's business development.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.